

# References

- [1]  
World Health Organization **The evolving threat of antimicrobial resistance: options for action** WHO, Geneva (Switzerland) (2012)
- [2]  
European Center for Disease Prevention and Control (ECDC)/European Medicines Agency (EMA) **The bacterial challenge: time to react** ECDC/EMA, Stockholm (Sweden) (2009)
- [3]  
J. O'Neill **Antimicrobial resistance: tacking a crisis for the health and wealth of nations** HM Government, London (UK) (2014)
- [4]  
The White House **National action plan for combating antibiotic-resistant bacteria** The White House, Washington (DC) (2015)
- [5]  
D.M. Brogan, E. Mossialos **Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model** *Global Health*, 9 (2013), p. 58
- [6]  
V.M. D'Costa, C.E. King, L. Kalan, M. Morar, W.W.L. Sung, C. Schwarz, *et al.* **Antibiotic resistance is ancient** *Nature*, 477 (2011), pp. 457-461
- [7]  
V.M. Hughes, N. Datta **Conjugative plasmids in bacteria of the 'pre-antibiotic' era** *Nature*, 302 (1983), pp. 725-726
- [8]  
W.C. Albrich, D.L. Monnet, S. Harbarth **Antibiotic selection pressure and resistance in *Streptococcus pneumoniae* and *Streptococcus pyogenes*** *Emerg Infect Dis*, 10 (2004), pp. 514-517
- [9]  
P. Collignon, P. Athukorala, S. Senanayake, F. Khan **Antimicrobial resistance: the major contribution of poor governance and corruption to this growing problem** *PLoS ONE*, 10 (2015) e0116746
- [10]  
G. Levy Hara, C.F. Amábile-Cuevas, I. Gould, J. Hutchinson, L. Abbo, L. Saxynger, *et al.* **'Ten commandments' for the appropriate use of antibiotics by the practicing physician in an outpatient setting** *Front Microbiol*, 2 (2011), p. 230
- [11]  
C.M. van den Bosch, S.E. Geerlings, S. Natsch, J.M. Prins, M.E. Hulscher **Quality indicators to measure appropriate antibiotic use in hospitalized adults** *Clin Infect Dis*, 60 (2015), pp. 281-291
- [12]  
C. Pulcini, S. Defres, I. Aggarwal, D. Nathwani, P. Davey **Design of a 'day 3 bundle' to improve the reassessment of inpatient empirical antibiotic prescriptions** *J Antimicrob Chemother*, 61 (2008), pp. 1384-1388
- [13]  
N. Ottman, H. Smidt, W.M. de Vos, C. Belzer **The function of our microbiota: who is out there and what do they do?** *Front Microbiol*, 2 (2012), p. 104
- [14]  
L. Dethlefsen, D.A. Relman **Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation** *Proc Natl Acad Sci USA*, 108 (Suppl. 1) (2011), pp. 4554-4561
- [15]  
V. Ki, C. Rotstein **Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care** *Can J Infect Dis Med Microbiol*, 19 (2008), pp. 173-184
- [16]  
D.L. Stevens, A.L. Bisno, H.F. Chambers, E.P. Dellinger, E.J.C. Goldstein, S.L. Gorbach, *et al.* **Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America** *Clin Infect Dis*, 59 (2014), pp. 147-159
- [17]  
American Thoracic Society, Infectious Diseases Society of America **Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia** *Am J Respir Crit Care Med*, 171 (2005), pp. 388-416

[18]

T.M. Hooton, S.F. Bradley, D.D. Cardenas, R. Colgan, S.E. Geerlings, J.C. Rice, *et al.* **Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America** Clin Infect Dis, 50 (2010), pp. 625-663

[19]

J.E. McGowan Jr, R.C. Rose, N.F. Jacobs, D.R. Schaberg, R.W. Haley **Fever in hospitalized patients. With special reference to the medical service** Am J Med, 82 (1987), pp. 580-586

[20]

D.H. Bor, H.J. Makadon, G. Fridland, P. Dasse, A.L. Komaroff, M.D. Aronson **Fever in hospitalized medical patients: characteristics and significance** J Gen Intern Med, 3 (1988), pp. 119-125

[21]

D.R. Kaul, S.A. Flanders, J.M. Beck, S. Saint **Brief report: incidence, etiology, risk factors, and outcome of hospital-acquired fever: a systematic, evidence-based review** J Gen Intern Med, 21 (2006), pp. 1184-1187

[22]

J. Littmann, A.M. Viens **The ethical significance of antimicrobial resistance** Public Health Ethics, 8 (2015), pp. 209-224

[23]

A. Kumar, D. Roberts, K.E. Wood, B. Light, J.E. Parrillo, S. Sharma, *et al.*

**Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock**

Crit Care Med, 34 (2006), pp. 1589-1596

[24]

R.P. Dellinger, M.M. Levy, A. Rhodes, D. Annane, H. Gerlach, S.M. Opal, *et al.*

**Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012**

Crit Care Med, 41 (2013), pp. 580-637

[25]

P.G. Ambrose, S.M. Bhavnani, C.M. Rubino, A. Louie, T. Gumbo, A. Forrest, *et al.*

**Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore**

Clin Infect Dis, 44 (2007), pp. 79-86

[26]

J.W. Mouton, M.N. Dudley, O. Cars, H. Derendorf, G.L. Drusano

**Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update**

J Antimicrob Chemother, 55 (2005), pp. 601-607

[27]

G.L. Daikos, S. Tsaousi, L.S. Tzouveleki, I. Anyfantis, M. Psychogiou, A. Argyropoulou, *et al.*

**Carbapenemase-producing *Klebsiella pneumoniae* bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems**

Antimicrob Agents Chemother, 58 (2014), pp. 2322-2328

[28]

G. Levy Hara, I. Gould, A. Endimiani, P.R. Pardo, G. Daikos, P.R. Hsueh, *et al.*

**Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an international working group**

J Chemother, 25 (2013), pp. 129-140

[29]

M. Akova, G.L. Daikos, L. Tzouveleki, Y. Carmeli

**Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria**

Clin Microbiol Infect, 18 (2012), pp. 439-448

[30]

J.L. Kuti, P.K. Dandekar, C.H. Nightingale, D.P. Nicolau

**Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem**

J Clin Pharmacol, 43 (2003), pp. 1116-1123

[31]

G.H. Ross, D.H. Wright, J.C. Rotschafer, K.H. Ibrahim

**Glycopeptide pharmacodynamics**

C.H. Nightingale, T. Murakawa, P.G. Ambrose (Eds.), Antimicrobial pharmacodynamics in theory and clinical practice, Marcel Dekker, New York (NY) (2001)

[32]

W.A. Craig

**Pharmacodynamics of antimicrobials: general concepts and applications**

C.H. Nightingale, T. Murakawa, P.G. Ambrose (Eds.), *Antimicrobial pharmacodynamics in theory and clinical practice*, Marcel Dekker, New York (NY) (2001)

[33]

M. Rybak, B. Lomaestro, J.C. Rotschafer, R.C. Moellering, W. Craig, M. Billeter, *et al.*

**Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists**

*Am J Health Syst Pharm*, 66 (2009), pp. 82-98

[34]

L.K. Hidayat, D.I. Hsu, R. Quist, K.A. Shriner, A. Wong-Beringer

**High-dose vancomycin therapy for methicillin-resistant *Staphylococcus aureus* infections: efficacy and toxicity**

*Arch Intern Med*, 166 (2006), pp. 2138-2144

[35]

T.P. Lodise, J. Graves, A. Evans, E. Graffunder, M. Helmecke, B.M. Lomaestro, *et al.*

**Relationship between vancomycin MIC and failure among patients with methicillin-resistant *Staphylococcus aureus* bacteremia treated with vancomycin**

*Antimicrob Agents Chemother*, 52 (2008), pp. 3315-3320

[36]

A. Soriano, F. Marco, J.A. Martínez, E. Pisos, M. Almela, V.P. Dimova, *et al.*

**Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant *Staphylococcus aureus* bacteremia**

*Clin Infect Dis*, 46 (2008), pp. 193-200

[37]

L. Pagani

**Rejuvenating aminoglycosides usage in geriatric patients with Gram-negative infections**

*Eur Geriatr Med*, 5 (2014), pp. 139-143

[38]

C. McKenzie

**Antibiotic dosing in critical illness**

*J Antimicrob Chemother*, 66 (Suppl. 2) (2011), pp. ii25-31

[39]

M.A. Zeitlinger, H. Derendorf, J.W. Mouton, O. Cars, W.A. Craig, D. Andes, *et al.*

**Protein binding: do we ever learn?**

*Antimicrob Agents Chemother*, 55 (2011), pp. 3067-3074

[40]

S. Esposito, I. Esposito, S. Leone

**Considerations of antibiotic therapy duration in community- and hospital-acquired bacterial infections**

*J Antimicrob Chemother*, 67 (2012), pp. 2570-2575

[41]

R. Pugh, C. Grant, R.P. Cooke, G. Dempsey

**Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults**

*Cochrane Database Syst Rev* (10) (2011)

CD007577

[42]

P. Schuetz, B. Müller, M. Christ-Crain, D. Stolz, M. Tamm, L. Bouadma, *et al.*

**Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections**

*Cochrane Database Syst Rev* (9) (2012)

CD007498

[43]

R.G. Sawyer, J.A. Claridge, A.B. Nathens, O.D. Rotstein, T.M. Duane, H.L. Evans, *et al.*

**Trial of short-course antimicrobial therapy for intraabdominal infection**

*N Engl J Med*, 372 (2015), pp. 1996-2005

[44]

J.S. Solomkin, J.E. Mazuski, J.S. Bradley, K.A. Rodvold, E.J. Goldstein, E.J. Baron, *et al.*

**Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America**

Clin Infect Dis, 50 (2010), pp. 133-164

[45]

S. Esposito, S. Leone, G. Carosi

**Analysis of current guidelines for intra-abdominal infections**

J Chemother, 21 (Suppl. 1) (2009), pp. 30-35

[46]

J. Chastre, M. Wolff, J.Y. Fagon, S. Chevret, F. Thomas, D. Wermert, *et al.*

**Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial**

JAMA, 290 (2003), pp. 2588-2598

[47]

G. Dimopoulos, G. Poulakou, I.A. Pneumatikos, A. Armaganidis, M.H. Kollef, D.K. Matthaiou

**Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis**

Chest, 144 (2013), pp. 1759-1767

[48]

K.G. Kyriakidou, P. Rafailidis, D.K. Matthaiou, S. Athanasiou, M.E. Falagas

**Short- versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trials**

Clin Ther, 30 (2008), pp. 1859-1868

[49]

N. Daneman, K. Shore, R. Pinto, R. Fowler

**Antibiotic treatment duration for bloodstream infections in critically ill patients: a national survey of Canadian infectious diseases and critical care specialists**

Int J Antimicrob Agents, 38 (2011), pp. 480-485

[50]

P.A. Tambyah, G. Levy Hara, G.L. Daikos, M.E. Falagas, T. Mazzei, J.W. Mouton, *et al.*

**Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012**

J Glob Antimicrob Resist, 1 (2013), pp. 117-122

[51]

J.G. Kmeid, M.M. Youssef, Z.A. Kanafani, S.S. Kanj

**Combination therapy for Gram-negative bacteria: what is the evidence?**

Expert Rev Anti Infect Ther, 11 (2013), pp. 1355-1362

[52]

P.D. Tamma, S.E. Cosgrove, L.L. Maragakis

**Combination therapy for treatment of infections with Gram-negative bacteria**

Clin Microbiol Rev, 25 (2012), pp. 450-470

[53]

M. Paul, I. Benuri-Silbiger, K. Soares-Weiser, L. Leibovici

**$\beta$ -Lactam monotherapy versus  $\beta$  lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomized trials**

BMJ, 328 (2004), p. 668

[54]

N. Safdar, J. Handelsman, D.G. Maki

**Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis**

Lancet Infect Dis, 4 (2004), pp. 519-527

[55]

K.Z. Vardakas, G.S. Tansarli, I.A. Bliziotis, M.E. Falagas

**$\beta$ -Lactam plus aminoglycoside or fluoroquinolone combination versus  $\beta$ -lactam monotherapy for *Pseudomonas aeruginosa* infections: a meta-analysis**

Int J Antimicrob Agents, 41 (2013), pp. 301-310

[56]

A. Kumar, R. Zarychanski, B. Light, J. Parrillo, D. Maki, D. Simon, *et al.*

**Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis**

Crit Care Med, 38 (2010), pp. 1773-1785

[57]

A. Batirel, I.I. Balkan, O. Karabay, C. Agalar, S. Akalin, O. Alici, *et al.*

**Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant *Acinetobacter baumannii* bloodstream infections**

Eur J Clin Microbiol Infect Dis, 33 (2014), pp. 1311-1322

[58]

P. Poulidakos, G.S. Tansarli, M.E. Falagas

**Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant *Acinetobacter* infections: a systematic review**

Eur J Clin Microbiol Infect Dis, 33 (2014), pp. 1675-1685

[59]

A. Reinhardt, T. Köhler, P. Wood, P. Rohner, J.L. Dumas, B. Ricou, *et al.*

**Development and persistence of antimicrobial resistance in *Pseudomonas aeruginosa*: a longitudinal observation in mechanically ventilated patients**

Antimicrob Agents Chemother, 51 (2007), pp. 1341-1350

[60]

M. Tumbarello, P. Viale, C. Viscoli, E.M. Trecarichi, F. Tumietto, A. Marchese, *et al.*

**Predictors of mortality in bloodstream infections caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*: importance of combination therapy**

Clin Infect Dis, 55 (2012), pp. 943-950

[61]

M. Tumbarello, E.M. Trecarichi, F.G. De Rosa, M. Giannella, D.R. Giacobbe, M. Bassetti, *et al.*

**Infections caused by KPC-producing *Klebsiella pneumoniae*: differences in therapy and mortality in a multicentre study**

J Antimicrob Chemother, 70 (2015), pp. 2133-2143

[62]

M. Paul, Y. Carmeli, E. Durante-Mangoni, J.W. Mouton, E. Tacconelli, U. Theuretzbacher, *et al.*

**Combination therapy for carbapenem-resistant Gram-negative bacteria**

J Antimicrob Chemother, 69 (2014), pp. 2305-2309

[63]

E. Weiss, J.R. Zahar, P. Lesprit, E. Ruppe, M. Leone, J. Chastre, *et al.*

**Elaboration of a consensual definition of de-escalation allowing a ranking of  $\beta$ -lactams**

Clin Microbiol Infect, 21 (2015), p. 649

e1-10

[64]

F. Baquero

**Evolving resistance patterns of *Streptococcus pneumoniae*: a link with long-acting macrolide consumption?**

J Chemother, 11 (Suppl. 1) (1999), pp. 35-43

[65]

C.F. Amábile-Cuevas

**Antibiotic resistance: from Darwin to Lederberg to Keynes**

Microb Drug Resist, 19 (2013), pp. 73-87

[66]

H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, L.B. Rice, *et al.*

**Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America**

Clin Infect Dis, 48 (2009), pp. 1-12

[67]

A.M. Rogues, C. Dumartin, B. Amadéo, A.G. Venier, N. Marty, P. Parneix, *et al.*

**Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in *Staphylococcus aureus* and *Pseudomonas aeruginosa* isolates from 47 French hospitals**

Infect Control Hosp Epidemiol, 28 (2007), pp. 1389-1395

[68]

E.M. Graffunder, R.A. Venezia

**Risk factors associated with nosocomial methicillin-resistant *Staphylococcus aureus* (MRSA) infection including previous use of antimicrobials**

J Antimicrob Chemother, 49 (2002), pp. 999-1005

[69]

H. Gbaguidi-Haore, C. Dumartin, F. L'Hériteau, M. Péfau, D. Hocquet, A.M. Rogues, *et al.*

**Antibiotics involved in the occurrence of antibiotic-resistant bacteria: a nationwide multilevel study suggests differences within antibiotic classes**

J Antimicrob Chemother, 68 (2013), pp. 461-470

[70]

K. Miliani, F. L'Hériteau, L. Lacavé, A. Carbonne, P. Astagneau, Antimicrobial Surveillance Network Study Group

**Imipenem and ciprofloxacin consumption as factors associated with high incidence rates of resistant *Pseudomonas aeruginosa* in hospitals in northern France**

J Hosp Infect, 77 (2011), pp. 343-347

[71]

P.R. Hsueh, Chen W.H., K.T. Luh

**Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991–2003 at a university hospital in Taiwan**

Int J Antimicrob Agents, 26 (2005), pp. 463-472

[72]

M.J. Dinubile, I. Friedland, C.Y. Chan, M.R. Motyl, H. Giezek, M. Shivaprakash, *et al.*

**Bowel colonization with resistant Gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy**

Eur J Clin Microbiol Infect Dis, 24 (2005), pp. 443-449

[73]

A. Agodi, F. Auxilia, M. Barchitta, S. Brusaferrò, M.M. D'Errico, M.T. Montagna, *et al.*

**Antibiotic consumption and resistance: results of the SPIN-UTI project of the GISIO-SItI**

Epidemiol Prev, 39 (Suppl. 1) (2015), pp. 94-98

[74]

A.L. Pakys, M. Oinonen, R.E. Polk

**Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant *Pseudomonas aeruginosa***

Antimicrob Agents Chemother, 53 (2009), pp. 1983-1986

[75]

G. Petrikos, A. Markogiannakis, J. Papaparaskevas, G. Daikos, G. Stefanakos, N.P. Zissis, *et al.*

**Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among *Klebsiella pneumoniae* and *Escherichia coli* clinical isolates following a restriction policy in a Greek tertiary care hospital**

Int J Antimicrob Agents, 29 (2007), pp. 34-38

[76]

P.N. Harris, J.K. Ferguson

**Antibiotic therapy for inducible AmpC  $\beta$ -lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides?**

Int J Antimicrob Agents, 40 (2012), pp. 297-305

[77]

M. Hilty, P. Sendi, S.N. Seiffert, S. Droz, V. Perreten, A.M. Hujer, *et al.*

**Characterization and clinical features of *Enterobacter cloacae* bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?**

Int J Antimicrob Agents, 41 (2013), pp. 236-249

[78]

A. Endimiani, F. Perez, R.A. Bonomo

**Cefepime: a reappraisal in an era of increasing antimicrobial resistance**

Expert Rev Anti Infect Ther, 6 (2008), pp. 805-824

[79]

P.D. Tamma, S.C. Girdwood, R. Gopaul, T. Tekle, A.A. Roberts, A.D. Harris, *et al.*

**The use of cefepime for treating AmpC  $\beta$ -lactamase-producing Enterobacteriaceae**

Clin Infect Dis, 57 (2013), pp. 781-788

[80]

D.E. Karageorgopoulos, Wang R., Yu X.H., M.E. Falagas

**Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens**

J Antimicrob Chemother, 67 (2012), pp. 255-268

[81]

J.C. Marshall, R.V. Maier, M. Jimenez, E.P. Dellinger **Source control in the management of severe sepsis and septic shock: an evidence-based review** Crit Care Med, 32 (Suppl. 11) (2004), pp. S513-26

[82]

L.A. Mermel, M. Allon, E. Bouza, D.E. Craven, P. Flynn, N.P. O'Grady, *et al.*

**Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America**

Clin Infect Dis, 49 (2009), pp. 1-45

[83]

J. Garnacho-Montero, A. Gutiérrez-Pizarraya, A. Escosca-Ortega, Y. Corcia-Palomo, E. Fernández-Delgado, I. Herrera-Melero, *et al.* **De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock**

Intensive Care Med, 40 (2014), pp. 32-40

[84]

D. Mokart, G. Slehofer, J. Lambert, A. Sannini, L. Chow-Chine, J.P. Brun, *et al.*

**De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study** Intensive Care Med, 40 (2014), pp. 41-49

[85]

A. Tabah, M.O. Cotta, J. Garnacho-Montero, J. Schouten, J.A. Roberts, J. Lipman, *et al.*

**A systematic review of the definitions, determinants, and clinical outcomes of antimicrobial de-escalation in the intensive care unit**

Clin Infect Dis, 62 (2016), pp. 1009-1017

[86]

N. Singh, P. Rogers, C.W. Atwood, M.M. Wagener, Yu V.L. **Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription** Am J Respir Crit Care Med, 162 (2000), pp. 505-511

[87]

US Centers for Disease Control and Prevention **Core elements of hospital antibiotic stewardship programs** CDC, Atlanta (GA) (2014)

[88]

T.H. Dellit, R.C. Owens, J.E. McGowan, D.N. Gerding, R.A. Weinstein, J.P. Burke, *et al.*

**Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship** Clin Infect Dis, 44 (2007), pp. 159-177

[89]

P. Howard, C. Pulcini, G. Levy Hara, R.M. West, I.M. Gould, S. Harbarth, *et al.*

**An international cross-sectional survey of antimicrobial stewardship programmes in hospitals** J Antimicrob Chemother, 70 (2015), pp. 1245-1255

[90]

G. Levy Hara **Antimicrobial stewardship in hospitals: does it work and can we do it?** J Glob Antimicrob Resist, 2 (2014), pp. 1-6

[91]

C. Pulcini, E. Botelho-Nevers, O.J. Dyar, S. Harbarth **The impact of infectious disease specialists on antibiotic prescribing in hospitals**

Clin Microbiol Infect, 20 (2014), pp. 963-972

[92]

S. Schmitt, D.P. McQuillen, R. Ronald Nahass, L. Martinelli, M. Rubin, K. Schwebke, *et al.*

**Infectious diseases specialty intervention is associated with decreased mortality and lower healthcare costs**

Clin Infect Dis, 58 (2014), pp. 22-28

[93]

C.F. Amábile-Cuevas **Antibiotics and antibiotic resistance in the environment**

CRC Press/Balkema, London (UK) (2016)